The effect of β-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis

Clinical Immunology

Volumn 129, Issue 1, 2008, Pages 80-89

  Hedegaard, Chris J ^a   Krakauer, Martin ^b   Bendtzen, Klaus ^a   Sørensen, Per Soelberg ^b   Sellebjerg, Finn ^b   Nielsen, Claus H ^a  

^a Rigshospitalet   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

Beta interferon; CD4+ T cells; Gamma interferon; IL 17; IL 6; Multiple sclerosis; Myelin basic protein; Tetanus toxoid

Indexed keywords

BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; MYELIN BASIC PROTEIN; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIODIVERSITY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; IMMUNOTHERAPY; LONGITUDINAL STUDY; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; FEMALE; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; TETANUS TOXOID;

EID: 51249109920     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.06.007     Document Type: Article

References (45)

1. Ann Marrie R., and Rudick R.A. Drug Insight: interferon treatment in multiple sclerosis. Nat. Clin. Pract. Neurol. 2 (2006) 34-44
2. Calabresi P.A., Pelfrey C.M., Tranquill L.R., Maloni H., and McFarland H.F. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 49 (1997) 1111-1116
3. Sellebjerg F., and Sorensen T.L. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res. Bull. 61 (2003) 347-355
4. Genc K., Dona D.L., and Reder A.T. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J. Clin. Invest. 99 (1997) 2664-2671
5. Barna B.P., Chou S.M., Jacobs B., Yen-Lieberman B., and Ransohoff R.M. Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J. Neuroimmunol. 23 (1989) 45-53
6. Jiang H., Milo R., Swoveland P., Johnson K.P., Panitch H., and Dhib-Jalbut S. Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. J. Neuroimmunol. 61 (1995) 17-25
7. Pette M., Pette D.F., Muraro P.A., Farnon E., Martin R., and McFarland H.F. Interferon-beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. Neurology 49 (1997) 385-392
8. Rep M.H., Hintzen R.Q., Polman C.H., and van Lier R.A. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 67 (1996) 111-118
9. Rudick R.A., Carpenter C.S., Cookfair D.L., Tuohy V.K., and Ransohoff R.M. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 43 (1993) 2080-2087
10. Noronha A., Toscas A., and Jensen M.A. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J. Neuroimmunol. 46 (1993) 145-153
11. Nagai T., Devergne O., Mueller T.F., Perkins D.L., van Seventer J.M., and van Seventer G.A. Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J. Immunol. 171 (2003) 5233-5243
12. Zang Y.C., Skinner S.M., Robinson R.R., Li S., Rivera V.M., Hutton G.J., and Zhang J.Z. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult. Scler. 10 (2004) 499-506
13. Zang Y.C., Yang D., Hong J., Tejada-Simon M.V., Rivera V.M., and Zhang J.Z. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology 55 (2000) 397-404
14. Matusevicius D., Kivisakk P., Navikas V.V., Tian W., Soderstrom M., Fredrikson S., and Link H. Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. Eur. J. Neurol. 5 (1998) 265-275
15. Feng X., Yau D., Holbrook C., and Reder A.T. Type I interferons inhibit interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J. Interferon. Cytokine Res. 22 (2002) 311-319
16. Hamamcioglu K., and Reder A.T. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult. Scler. 13 (2007) 459-470
17. Roncarolo M.G., Bacchetta R., Bordignon C., Narula S., and Levings M.K. Type 1 T regulatory cells. Immunol. Rev. 182 (2001) 68-79
18. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., and de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174 (1991) 1209-1220
19. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., and de Vries J.E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174 (1991) 915-924
20. Del Prete G., De Carli M., Almerigogna F., Giudizi M.G., Biagiotti R., and Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 150 (1993) 353-360
21. C.J. Hedegaard, M. Krakauer, K. Bendtzen, H. Lund, F. Sellebjerg, and C.H. Nielsen, T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis, Immunology (2008).
22. Correale J., Gilmore W., McMillan M., Li S., McCarthy K., Le T., and Weiner L.P. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J. Immunol. 154 (1995) 2959-2968
23. Jones K.R., Farinas I., Backus C., and Reichardt L.F. Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell 76 (1994) 989-999
24. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., and Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201 (2005) 233-240
25. Bettelli E., Oukka M., and Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8 (2007) 345-350
26. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., and Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (2002) 500-508
27. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., and Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 5 (1999) 101-104
28. Ross C., Clemmesen K.M., Sorensen P.S., Koch-Henriksen N., and Bendtzen K. Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Mult. Scler. 12 (2006) 39-46
29. Nielsen C.H., Leslie R.G., Jepsen B.S., Kazatchkine M.D., Kaveri S.V., and Fischer E. Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulin-reactive CD4(+) T cells in healthy individuals. Eur. J. Immunol. 31 (2001) 2660-2668
30. Arbour N., Holz A., Sipe J.C., Naniche D., Romine J.S., Zyroff J., and Oldstone M.B. A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis. J. Neuroimmunol. 137 (2003) 197-209
31. Hallal-Longo D.E., Mirandola S.R., Oliveira E.C., Farias A.S., Pereira F.G., Metze I.L., Brandao C.O., Ruocco H.H., Damasceno B.P., and Santos L.M. Diminished myelin-specific T cell activation associated with increase in CTLA4 and Fas molecules in multiple sclerosis patients treated with IFN-beta. J. Interferon. Cytokine Res. 27 (2007) 865-873
32. Brod S.A., Marshall Jr. G.D., Henninger E.M., Sriram S., Khan M., and Wolinsky J.S. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 46 (1996) 1633-1638
33. Kozovska M.E., Hong J., Zang Y.C., Li S., Rivera V.M., Killian J.M., and Zhang J.Z. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 53 (1999) 1692-1697
34. Zafranskaya M., Oschmann P., Engel R., Weishaupt A., van Noort J.M., Jomaa H., and Eberl M. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis. Immunology 121 (2007) 29-39
35. Hawley A.E., Davis S.S., and Illum L. Targeting of colloids to lymph-nodes - influence of lymphatic physiology and colloidal characteristics. Adv. Drug Deliv. Rev. 17 (1995) 129-148
36. Panitch H.S., Hirsch R.L., Haley A.S., and Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1 (1987) 893-895
37. Calabresi P.A., Fields N.S., Farnon E.C., Frank J.A., Bash C.N., Kawanashi T., Maloni H., Jacobson S., and McFarland H.F. ELI-spot of Th-1 cytokine secreting PBMC's in multiple sclerosis: correlation with MRI lesions. J. Neuroimmunol. 85 (1998) 212-219
38. Bakhiet M., Ozenci V., Withagen C., Mustafa M., Fredrikson S., and Link H. A new cell enzyme-linked immunosorbent assay demonstrates gamma interferon suppression by beta interferon in multiple sclerosis. Clin. Diagn. Lab. Immunol. 6 (1999) 415-419
39. Brod S.A., Nelson L.D., Khan M., and Wolinsky J.S. IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. Int. J. Neurosci. 90 (1997) 135-144
40. Byskosh P.V., and Reder A.T. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult. Scler. 1 (1996) 262-269
41. Sorensen P.S., Koch-Henriksen N., Ross C., Clemmesen K.M., and Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65 (2005) 33-39
42. Jansson A., Ernerudh J., Kvarnstrom M., Ekerfelt C., and Vrethem M. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients. Mult. Scler. 9 (2003) 440-445
43. Jensen J., Krakauer M., and Sellebjerg F. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b. Cytokine 29 (2005) 24-30
44. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
45. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., le Page E., Edan G., McDonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Sorensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sa M., Salemi G., Savettieri G., Hillert J., and Compston D.A. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64 (2005) 1144-1151